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Purpose: To determine serum 25(OH)D and 1,25(OH)2D relationship with hepatitis B vaccination 2 
(study-1). Then, to investigate the effects on hepatitis B vaccination of achieving vitamin D 3 
sufficiency (serum 25(OH)D ≥50 nmol/L) by a unique comparison of simulated-sunlight and oral 4 
vitamin D3 supplementation in wintertime (study-2). Methods: Study-1 involved 447 adults. In 5 
study-2, 3 days after the initial hepatitis B vaccination, 119 men received either placebo, 6 
simulated-sunlight (1.3x standard-erythema dose, 3x/week for 4-weeks and then 1x/week for 8-7 
weeks) or oral vitamin D3 (1,000 IU/day for 4-weeks and 400 IU/day for 8-weeks). We measured 8 
hepatitis B vaccination efficacy as percentage of responders with anti-hepatitis B surface antigen 9 
immunoglobulin G ≥10 mIU/mL. Results: In study-1, vaccine response was poorer in persons 10 
with low vitamin D status (25(OH)D ≤40 vs 41–71 nmol/L mean difference[95% confidence 11 
interval] -15%[-26, -3%]; 1,25(OH)2D ≤120 vs ≥157 pmol/L -12%[-24%, -1%]). Vaccine 12 
response was also poorer in winter than summer (-18%[-31%, -3%]), when serum 25(OH)D and 13 
1,25(OH)2D were at seasonal nadirs, and 81% of persons had serum 25(OH)D <50 nmol/L. In 14 
study-2, vitamin D supplementation strategies were similarly effective in achieving vitamin D 15 
sufficiency from the winter vitamin D nadir in almost all (~95%); however, the supplementation 16 
beginning 3 days after the initial vaccination did not effect the vaccine response (vitamin D vs 17 
placebo 4%[-21%, 14%]). Conclusion:  Low vitamin D status at initial vaccination was 18 
associated with poorer hepatitis B vaccine response (study-1); however, vitamin D 19 
supplementation commencing 3 days after vaccination (study-2) did not influence the vaccination 20 
response. 21 
 22 






Discovery of the vitamin D receptor in almost all immune cells, and the many roles vitamin D 25 
has in innate and adaptive arms of immunity [1-3], highlight the importance of vitamin D in the 26 
regulation of immune responses [4]. As such, avoiding low serum 25-hydroxyvitamin D 27 
(25(OH)D) and achieving vitamin D sufficiency (25(OH)D ≥50 nmol/L) may be important for 28 
the development of vaccine responses and consequently public health [5]. Cell and animal studies 29 
indicate that vitamin D may modulate vaccine responses through 1,25-dihydroxyvitamin D 30 
(1,25(OH)2D) interaction with antigen presentation [6], dendritic cell migration, and the 31 
subsequent activation of T and B cell antibody responses [7-9]. Indeed, vitamin D 32 
supplementation that corrected wintertime vitamin D status to achieve sufficiency before a 33 
tetanus toxoid booster vaccination resulted in higher IgG antibody concentration compared to a 34 
placebo [10].  35 
 36 
The influence of vitamin D on the development of the hepatitis B vaccination response in humans 37 
remains unclear; previous investigations have only studied chronic kidney patients and report 38 
conflicting findings [11,12]. Moreover, the relationship between the biologically active form of 39 
vitamin D, 1,25(OH)2D, and hepatitis B vaccine is yet to be examined. Hepatitis B vaccination 40 
has previously been shown to be influenced by genetics and lifestyle factors [13-15] with 10–41 
15% of adults responding inadequately by producing too few antibodies, as dictated by an anti-42 
hepatitis B surface antigen immunoglobulin G (IgG) concentration of less than 10 mIU/mL [16]. 43 
Conversely, those responding to the vaccination with IgG concentration of 10 mIU/mL or more 44 
are generally accepted to be protected against infection clinically [16,17]. Whether vitamin D 45 
influences the development of hepatitis B vaccination in healthy adults is unknown, but important 46 





months [18-20]; and many adults remain unvaccinated because childhood vaccine coverage is 48 
~90% or less and routine infant hepatitis B vaccination began only recently in some countries 49 
(e.g. UK [21-23]). The hepatitis B vaccination course presents a suitable model to study the 50 
influence of vitamin D on the secondary immune response because there is widespread inter-51 
individual variability in the magnitude of the antibody response after the second vaccination, and 52 
it is more possible to control prior exposure than with other commonly experienced vaccines (e.g. 53 
influenza) [24]. 54 
 55 
Here we present results from two studies examining the influence of vitamin D on hepatitis B 56 
vaccine response. In these studies we measured 1,25(OH)2D, vitamin D’s biologically active 57 
form, and 25(OH)D, which with their respective 4–6 h and 2–3 week half lives can be considered 58 
acute and chronic vitamin D status markers, respectively [25]. In study 1, a prospective cohort 59 
study of 447 healthy young men and women conducted during all seasons, we examined for the 60 
first time serum 1,25(OH)2D and 25(OH)D relationship with hepatitis B vaccination in healthy 61 
adults. We hypothesized that low serum 1,25(OH)2D and 25(OH)D at the time of initial 62 
vaccination would be associated with poorer secondary antibody response to hepatitis B 63 
vaccination. In study 2, a randomized placebo-controlled trial, we determined the effect of 12-64 
weeks wintertime vitamin D supplementation on the hepatitis B vaccination response. The 65 
supplementation was a unique comparison of simulated sunlight in accordance with 66 
recommendations on safe (non-sunburning), low-level sunlight exposure [26], and oral vitamin 67 
D3 to achieve vitamin D sufficiency (serum 25(OH)D ≥50 nmol/L). Vitamin D sufficiency was 68 
targeted as maintaining serum 25(OH)D concentration ≥50 nmol/L has been recommended for 69 
multiple health outcomes [27] by the Institute of Medicine (IOM) and European Food Safety 70 





vitamin D can be obtained from dietary sources but is predominately synthesized by skin 72 
exposure to solar ultraviolet (UV) B radiation; UV radiation has a range of vitamin D-dependent 73 
and -independent effects on immunity [28,29]. We hypothesized that vitamin D supplementation 74 
that achieves vitamin D sufficiency during winter when vitamin D status is usually low would 75 
lead to superior secondary antibody response to hepatitis B vaccination compared to placebo 76 
supplementation.  77 
 78 
Methods 79 
The Ministry of Defence (UK) Research Ethics Committee approved these studies, and protocols 80 
were conducted in accordance with the Declaration of Helsinki (2013). All participants provided 81 
written informed consent.  82 
 83 
Study 1 84 
Participant recruitment, inclusion and exclusion criteria  85 
Between June 2014 and November 2015, 1268 men and women who entered the British Army 86 
were assessed for eligibility for this prospective cohort study. Eligible participants were ≥18 87 
years of age. One thousand one hundred and three recruits volunteered (men from the Infantry 88 
Training Centre, Catterick, UK; latitude 54°N, and women from the Army Training Centre, 89 
Pirbright, UK; latitude 51°N). Participants were excluded from the final analysis if they failed the 90 
initial medical assessment, followed an atypical hepatitis B vaccination schedule (the first two 91 
vaccine doses were not administered within 4 weeks of each other), or did not provide a blood 92 
sample to assess the secondary hepatitis B vaccine response. Participants were also excluded 93 





vaccination; or, if this was later confirmed by measurable antibody titers against hepatitis B 95 
surface antigen detected in baseline samples (anti-HBs titers >0 mIU/mL). The baseline 96 
demographics, anthropometrics, and lifestyle behaviors for the 447 participants included in the 97 
final analysis are summarized in Table 1 (Supplemental Table 1 includes details of the larger 98 
recruited sample). 99 
 100 
Procedures 101 
Before participants commenced Basic Military training they completed an initial medical 102 
assessment. During the initial medical assessment, participants received their first 20-μg dose of 103 
recombinant hepatitis B vaccine into the deltoid muscle (Engerix–B, Smithkline Beecham 104 
Pharmaceuticals, Uxbridge, UK) and a venous blood sample was collected for the determination 105 
of hepatitis B antibody titer, serum 25(OH)D and 1,25(OH)2D concentrations (Figure 1). At the 106 
initial medical assessment, we also collected baseline measures of participant demographics (e.g. 107 
ethnicity) and anthropometrics; height and body mass were assessed in light clothing with shoes 108 
removed by stadiometer and digital platform scale, respectively (SECA 703, Birmingham, UK). 109 
Lifestyle factors previously shown to influence the vaccination response were also assessed by 110 
questionnaire; including alcohol and smoking use, sleep and mood [13,15,14]. To assess sleep 111 
duration and quality the night before vaccination participants completed a questionnaire based on 112 
the procedures of Prather et al [15]. Sleep duration was calculated as the number of hours and 113 
minutes elapsed between the time they reported going to sleep and the time they reported waking. 114 
Sleep quality was reported on a scale from 1 = very poor to 4 = very good. Before receiving their 115 
initial hepatitis B vaccination participants also completed a Brunel mood scale (BRUMS) [30], 116 





assessed by 4 items scored from 0 = not at all to 4 = extremely and therefore the maximum score 118 
per mood is 20, with greater scores indicating a greater feeling of the mood. In line with the 119 
typical hepatitis B vaccination schedule, participants received a second 20-μg hepatitis B vaccine 120 
dose one month after the first. A second venous blood sample was collected 8 weeks after the 121 
second hepatitis B vaccine dose (3-months after the first hepatitis B vaccine dose) to determine 122 
secondary serum hepatitis B antibody titers, the primary outcome measure. The serum hepatitis B 123 
antibody titer (anti-HBs) was assessed as this is the routine serological test to determine if a 124 
person has been successfully vaccinated against hepatitis B [16]. We focused on the antibody 125 
response to the second vaccination because there is widespread inter-individual variability in the 126 
magnitude of antibody response following the second vaccination of the typical three-dose series 127 
[24]. This variability is in distinct contrast with the antibody response to the first vaccination, 128 
when <10% of individuals have detectable levels of antibody, or the third, when the majority of 129 
individuals have mounted maximal antibody responses, respectively [15]. ‘All-cause illness’ 130 
consisting of physician diagnosed cases of upper and lower respiratory tract infection and 131 
gastrointestinal infection were also retrieved from medical records for the period of basic 132 
training. 133 
 134 
Study 2 135 
Participant recruitment and exclusion criteria  136 
Healthy men were recruited in a double-blind randomized, placebo-controlled trial upon entering 137 
the British Army Combat Infantryman’s Course, Catterick, UK during January and February of 138 
2016 and 2017, when ambient UVB is negligible at UK latitudes (50–60°N), and serum 25(OH)D 139 





assessment; had no history of skin cancer, photosensitivity, or lupus erythematosus; and had sun-141 
reactive skin type I–IV [31]. Participants were excluded for the same reasons as in study 1, plus 142 
current consumption of vitamin D in dietary supplements; use of a sunbed or travel to a sunny 143 
climate 3-months before the study.  144 
 145 
Experimental procedures 146 
Participants had the same baseline assessments and hepatitis B vaccination schedule as study 1 147 
(Figure 1). Following this, we block randomized participants within their platoons to one of four 148 
intervention groups: 1) solar simulated radiation (SSR); 2) solar simulated radiation placebo 149 
(SSR-P); 3) oral vitamin D3 (ORAL); or 4) oral placebo (ORAL-P). Block randomization by 150 
randomizer.org resulted in an equal distribution of intervention groups within each platoon, and 151 
ensured any differences in training conditions between platoons did not influence the study 152 
outcomes. An independent researcher completed the randomization and investigators were blind 153 
to the randomization until statistical analyses were completed. The interventions began 3 days 154 
after the initial hepatitis B vaccine dose. The intervention strategy for the SSR and ORAL groups 155 
was to restore and then maintain vitamin D sufficiency (serum 25(OH)D ≥50 nmol/L) as 156 
recommended by Institute of Medicine (IOM) and the European Food Safety Authority (EFSA) 157 
[19,20]. Participants completed a 4-week restoration phase, necessary because serum 25(OH)D 158 
was at its winter nadir, followed by an 8-week maintenance phase (Figure 1). Blood samples 159 
were obtained at baseline, and after 5 and 12 weeks for the determination of serum 25(OH)D and 160 
1,25(OH)2D (Figure 1). Vitamin D from solar UV radiation exposure was estimated in weeks 4 161 





questionnaire [32]. On completion of the study, participants completed an ‘exit survey,’ which 163 
required them to guess the intervention they thought they had been receiving. 164 
 165 
Simulated sunlight intervention 166 
In accordance with guidelines on safe, low-level sunlight exposure for vitamin D synthesis [26], 167 
and as described previously to achieve vitamin D sufficiency (serum 25(OH)D ≥50 nmol/L) in 168 
the majority of white skinned persons [33], those assigned to the SSR intervention were exposed 169 
three-times-a-week, during the restoration phase to an investigator controlled constant UV 170 
radiation dose using a whole body irradiation cabinet (Hapro Jade, Kapelle, The Netherlands) 171 
fitted with Arimed B fluorescent tubes (Cosmedico, Stuttgart, Germany). The fluorescent tubes 172 
emitted a UV radiation spectrum similar to sunlight (λ: 290–400 nm; 95% UVA: 320–400 nm, 173 
5% UVB: 290–320 nm) that was characterized by a spectroradiometer (USB2000+, Ocean Optics 174 
BV, Duiven, The Netherlands) radiometrically calibrated with traceability to UK national 175 
standards. During each exposure participants received a 1.3 standard erythemal dose (SED), and 176 
wore shorts and a T-shirt to expose ~40% of skin surface area. This dose is equivalent to ~15 177 
minutes midday summer sun exposure in northern England (latitude 53.5°N) [33] and taking 178 
account of pre-vitamin D irradiance at different latitudes, can be related to exposure times at 179 
other world locations [34]. For example, the equivalent exposure time in Philadelphia, 180 
Pennsylvania, USA (40°N) would be ~12 minutes; and that for Oslo, Norway (60°N) would be 181 
~18 minutes. During the maintenance phase, we exposed SSR participants to the same 1.3x SED 182 
dose only once-a-week: pilot investigations confirmed the required dose to maintain sufficiency 183 
(serum 25(OH)D ≥50 nmol/L). A constant SSR dose was maintained during the study by 184 





for any decrease in measured irradiance emitted by increasing exposure time (mean duration of 186 
SSR exposures was 229 ± 17 s). We controlled the exposure time by using an electronic timer. 187 
Participants undergoing SSR-P treatment received the same number of intervention exposures 188 
each week and the exposure duration as SSR except the irradiation cabinet fluorescent tubes were 189 
covered with transparent UV radiation blocking film (DermaGard UV film, SunGard, Woburn, 190 
Massachusetts, USA) [35] in a manner invisible to the participants and experimenters. 191 
Spectroradiometry confirmed the UV radiation blocking film was effective at preventing 192 
transmission of 99.9% of UV radiation. 193 
 194 
Oral vitamin D3 intervention 195 
Participants receiving the ORAL intervention consumed a daily vitamin D3 supplement 196 
containing 1000 IU and 400 IU vitamin D3 during the restoration phase and maintenance phases, 197 
respectively (Pure Encapsulations, Sudbury, Massachusetts, USA) [35]. The restoration dose 198 
(1000 IU/day) was based on previous predictive modelling to achieve serum 25(OH)D ≥50 199 
nmol/L [36], and pilot investigations that showed it achieved similar serum 25(OH)D 200 
concentrations to SSR; and was less than the tolerable upper intake recommended by IOM and 201 
EFSA [19,20]. The ORAL maintenance dose (400 IU/day) was in accordance with 202 
recommendations [19]. For 12-weeks, ORAL-P participants consumed a daily oral cellulose 203 
placebo capsule, identical in size, shape and color to the vitamin D3 capsules (Almac Group, 204 
County Armagh, UK). Independent analysis found the vitamin D3 content of the 1000 and 400 IU 205 
capsules to be 1090 and 460 IU, respectively and confirmed the placebo did not contain vitamin 206 






Biochemical analyses (Study 1 and 2) 209 
Whole blood samples were collected by venepuncture from an antecubital vein into plain 210 
vacutainer tubes (Becton Dickinson, Oxford, UK) and left to clot for one hour. Subsequently, 211 
samples were centrifuged at 1500 g for 10 min at 4°C and the serum aliquoted into eppendorf 212 
tubes before being immediately frozen at -80°C for later analysis. Baseline and secondary serum 213 
antibody titers were determined using a hepatitis B antibody enzyme-linked immunoassay kit 214 
(DiaSorin, Saluggia, Italy). The intra-assay coefficient of variation was 4.9% (study 1) and 5.9% 215 
(study 2). Total serum 25(OH)D was measured with high-pressure liquid chromatography tandem 216 
mass spectrometry [37]; and serum 1,25(OH)2D using the DiaSorin LIAISON XL 1,25(OH)2D 217 
chemiluminescent immunoassay (Stillwater, Minnesota, USA) method. Analyses were performed 218 
in a Vitamin D External Quality Assurance Scheme certified laboratory (Bioanalytical Facility, 219 
University of East Anglia, Norwich, UK).  220 
 221 
Statistical analysis  222 
Secondary antibody titers have a non-normal distribution and therefore, in line with previous 223 
research [17], we categorized the development of secondary antibody response to the hepatitis B 224 
vaccine as the percentage of participants with serum antibody titer response to hepatitis B ≥10 225 
mIU/mL. Those participants with anti-HBs titers ≥10 mIU/mL were categorized as vaccine 226 
‘responders’ whilst those with antibody titers <10 mIU/mL were categorized as vaccine ‘non-227 
responders’ [17]. Further, those responding to the vaccination with anti-HBs titers of 10 mIU/mL 228 
or more are generally accepted to be protected against infection clinically [17,16]. The sample 229 
size estimation for study 1 and 2 was calculated as a minimum of 152, using the anticipated 230 





size) between individuals displaying low and high vitamin D status [11], with a type 1 error (one 232 
tailed) of 5%, and a power of 80%. For study 1, we used chi-square analysis to compare the 233 
percentage of hepatitis B vaccine responders in those with IOM defined vitamin D sufficient 234 
status (serum 25(OH)D ≥50 nmol/L) compared to those with serum <50 nmol/L. However, as 235 
there is no consensus to the optimal vitamin D threshold for immune function [18,38], we 236 
conducted Kruskal Wallis tests to compare the percentage of hepatitis B vaccine responders 237 
across 25(OH)D, 1,25(OH)2D and 24,25(OH)2D terciles. One-way ANOVA and Kruskal-Wallis 238 
tests were used, where appropriate, to compare serum vitamin D (25(OH)D and 1,25(OH)2D), 239 
percentage of participants displaying serum 25(OH)D ≥50 nmol/L and the percentage of hepatitis 240 
B vaccine responders across seasons. Independent t-test, chi-square, One-way ANOVA and 241 
Kruskal-Wallis tests, were used, where appropriate, to compare demographic, anthropometric, 242 
alcohol and smoking use, sleep, mood, contraception use in women, ‘all-cause illnes ’data across 243 
seasons and between participants with serum 25(OH)D ≥50 nmol/L and <50 nmol/L. For study 2, 244 
Kruskal-Wallis was used to compare the percentage of secondary hepatitis B vaccine responders 245 
after SSR, ORAL, SSR-P and ORAL-P. In addition, the percentage of secondary hepatitis B 246 
vaccine responders was compared between vitamin D supplementation (SSR and ORAL 247 
combined) and placebo groups (SSR-P and ORAL-P combined) using chi-square analysis. Serum 248 
25(OH)D and 1,25(OH)2D were compared between vitamin D and placebo groups using mixed 249 
model ANOVA (4 group (SSR, ORAL, SSR-P and ORAL-P) x 3 time points (baseline, week 5 250 
and 12) and 2 group (SSR and ORAL combined, SSR-P and ORAL-P) x 3 time points. Post hoc 251 
comparisons were conducted using Bonferroni corrected t-tests. Chi-square tests were conducted 252 
to compare the percentage of participants displaying total serum 25(OH)D ≥50 nmol/L at 253 
baseline, week 5 and week 12 between vitamin D and placebo groups. Independent samples t-254 





alcohol and smoking use, sleep, and mood data between vitamin D and placebo supplement 256 
groups. All statistical analyses were completed using SPSS Statistics 22 (IBM, Armonk, New 257 
York, USA).  258 
 259 
Results  260 
Study 1  261 
Participant flow  262 
A total of 1103 men and women were recruited from June 2014 to November 2015. Participants 263 
began the study throughout the year: 20% in winter (December–February), 14% in spring 264 
(March–May), 26% in summer (June–August), and 40% in autumn (September–November). 265 
Participant flow, drop out and exclusion before biochemical and statistical analysis are 266 
summarized in Figure 2. There was no significant difference in demographics, anthropometrics, 267 
lifestyle behaviors, sleep, mood, contraception use, or all cause illness between participants 268 
included and excluded in the final analysis (Supplemental Table 2). 269 
 270 
Vitamin D and secondary hepatitis B vaccine response 271 
At the time of the initial vaccination 43% of participants had serum 25(OH)D <50 nmol/L, 26% 272 
were vitamin D insufficient (serum 25(OH)D 30–50 nmol/L), and 17% were vitamin D deficient 273 
(serum 25(OH)D <30 nmol/L). Only 1 participant presented with severe vitamin D deficiency 274 
(serum 25(OH)D <12.5 nmol/L). Fewer participants tended to respond to the hepatitis B 275 
vaccination who had 25(OH)D <50 nmol/L than those who were vitamin D sufficient at the time 276 
of initial vaccination (50% vs 58%, mean difference [95% confidence interval], -8% [-17%, 1%], 277 





serum 25(OH)D ≤40 nmol/L (mean 30 ± 7  nmol/L) compared to participants with 25(OH)D 279 
between 41–71 nmol/L (mean 56 ± 9 nmol/L) at the time of initial vaccination (mean difference 280 
[95% confidence interval -15% [-26%, -3%], P = 0.01, Figure 3B). Fewer participants were also 281 
hepatitis B vaccine responders when they presented with low serum 1,25(OH)2D compared to 282 
participants who presented with high serum 1,25(OH)2D at the time of initial vaccination (50% vs 283 
62%, mean difference [95% confidence interval] -12% [-24%, -1%,], P < 0.05, h = 0.24, Figure 284 
3C). Furthermore, fewer participants were hepatitis B vaccine responders when they presented 285 
with combined low 1,25(OH)2D and 25(OH)D compared to combined medium-high 25(OH)D 286 
and 1,25(OH)2D (43% vs 65%, mean difference [95% confidence interval], -22% [-39%, -5%], P 287 
= 0.01). No differences were observed between those who presented with low serum 288 
24,25(OH)D compared to participants who presented with high serum 24,25(OH)D at the time of 289 
initial vaccination (52% vs 60%, mean difference [95% confidence interval] -8% [20%, 3%], P = 290 
0.14). 291 
 292 
There were no differences between participants with 25(OH)D ≥50 nmol/L and <50 nmol/L in 293 
demographics, anthropometrics, lifestyle behaviors, sleep, mood, contraception use, or all cause 294 
illness before the initial hepatitis B vaccination (Table 2). Anthropometrics, lifestyle behaviors, 295 
sleep, mood and all cause illness also did not predict vaccine response (P > 0.05). Additionally, 296 
contraception use did not influence the vaccine response (P > 0.05, e.g. none vs oral 297 
contraception, 68% vs 62% mean difference [95% confidence interval] 6% [-9, 21%]). Further 298 
regression analysis controlling for BMI, smoking, alcohol, sleep and mood indicated that vitamin 299 
D sufficient men, but not women, were 1.8 times more likely to be vaccine responders than those 300 
with serum 25(OH)D <50 nmol/L (OR [95% confidence interval], men 1.8 [1.0, 3.2] and women 301 





B response was lower in men than women (P < 0.05, men vs women: 25(OH)D, 56 ± 30 vs 69 ± 303 
32 nmol/L; 1,25(OH)2D, 126 ± 32 vs 165 ± 43 pmol/L; 24,25(OH)2D, 4.4 ± 2.8 vs 6.5 ± 3.7 304 
nmol/L; vitamin D sufficiency, 49% vs 69%; hepatitis B response, 49% vs 65%).  305 
 306 
Seasonal variation in vitamin D and hepatitis B vaccine response 307 
Serum 25(OH)D, 1,25(OH)2D and vitamin D sufficiency (25(OH)D ≥50 nmol/L) was lower in 308 
winter than spring, summer and autumn (P < 0.05, Figure 4A, 4B & 4C). In winter, 81% 309 
participants had 25(OH)D <50 nmol/L (Figure 4B) with 32% of participants vitamin D deficient 310 
(serum 25(OH)D <30 nmol/L). The percentage of hepatitis B vaccine responders was also lower 311 
in winter than summer (44% vs 62%, mean difference [95% confidence interval] -18% [-31%, -312 
3%], P < 0.05, h = 0.36, Figure 4D). With the exception of all cause illness, participants 313 
recruited in the different seasons were similar as indicated by no differences in demographic, 314 
anthropometrics, lifestyle behaviors, sleep, mood or use of contraception in women before the 315 
initial hepatitis B vaccination (Table 1). Similar seasonal variations in serum 24,25(OH)2D were 316 
also observed with winter serum 24,25(OH)2D contrations lower than summer and autumn (P < 317 
0.05, winter 2.9 ± 2.2 nmol/L, spring 4.2 ± 2.8 nmol/L, summer 6.5 ± 3.2 nmol/L, autumn 5.9 ± 318 
3.4 nmol/L) 319 
 320 
Study 2 321 
Participant flow and blinding 322 
Two hundred and thirty-one men were assigned to the interventions in January and February of 323 
2016 and 2017. The study ended after reaching its scheduled date of closure. Participant flow, 324 
drop out and exclusion before biochemical and statistical analysis is summarized in Figure 5. 325 





or mood between participants included and excluded in the final analysis (Supplemental Table 3). 327 
There were no adverse events reported relating to vitamin D or placebo supplementation. 328 
Participants were sufficiently blinded to the intervention since only 35% correctly guessed their 329 
allocated group, 30% were incorrect, and 35% said they did not know whether they had received 330 
an active (SSR and ORAL) or placebo (SSR-P and ORAL-P) intervention.  331 
 332 
The influence of low-level simulated sunlight and oral vitamin D3 on vitamin D status  333 
At baseline, 75% of the volunteers had 25(OH)D <50 nmol/L, 45% were vitamin D insufficient 334 
(serum 25(OH)D 30–50 nmol/L), and 30% were vitamin D deficient (serum 25(OH)D <30 335 
nmol/L). Only 1 participant presented with severe vitamin D deficiency (serum 25(OH)D <12.5 336 
nmol/L). There was no difference between vitamin D and placebo supplementation groups’ 337 
demographics, anthropometrics, lifestyle behaviors, sleep, mood (Table 3), or vitamin D status 338 
(Figure 6, P > 0.05). There were also no differences in these variables between combined 339 
vitamin D and placebo supplemented groups (Supplemental Table 4 & Figure 6). During the 12-340 
week intervention, daily sunlight exposure was low, as expected considering the latitude and time 341 
of year [39], with similar sunlight exposure (0.22 ± 0.33 SED/day; P > 0.05) and dietary vitamin 342 
D intake (112 ± 84 IU/day, P > 0.05) in vitamin D and placebo supplement groups.  343 
 344 
The vitamin D supplementation was successful in achieving vitamin D sufficiency and 345 
maintaining serum 25(OH)D concentrations so that at week 5 and 12 serum 25(OH)D 346 
concentrations in the vitamin D supplementation groups were higher than the placebo groups (P 347 
< 0.05, Figure 6A & D). By week 5, 95% of participants in the vitamin D supplementation 348 





serum 25(OH)D or percentage of participants achieving vitamin sufficiency between vitamin D 350 
supplementation groups (P > 0.05). Serum 1,25(OH)2D was similar in all groups at baseline (P > 351 
0.05) and increased with supplementation (P < 0.05, Figure 6C & F), with greater responses in 352 
the vitamin D supplementation groups compared to the placebo groups at week 5 (P < 0.05). 353 
There was no difference between groups at week 12 (P > 0.05) because 1,25(OH)2D increased 354 
from week 5 to 12 in placebo groups (P < 0.05). Serum 24,25(OH)2D responded similarly to 355 
supplementation as serum 25(OH)D so that at week 5 and 12 serum 24,25(OH)2D concentrations 356 
in the vitamin D supplementation groups were higher than the placebo groups (P < 0.05, 357 
Supplemental Table 5). 358 
 359 
The influence of simulated sunlight and oral vitamin D3 on secondary hepatitis B vaccine 360 
response  361 
Vitamin D supplementation beginning 3 days after the initial vaccination did not influence the 362 
secondary antibody response as the percentage of secondary hepatitis B vaccine responders was 363 
similar among the vitamin D and placebo groups (SSR 60%, SSR-P 57%, ORAL 56%, ORAL-P 364 
52%, P > 0.05, Figure 7A). Analyses comparing combined vitamin D to placebo also revealed 365 
no effect of vitamin D supplementation on secondary hepatitis B vaccine response (SSR and 366 
ORAL vs SSR-P and ORAL-P, 58% vs 54%, mean difference [95% confidence interval], 4% [-367 
21%, 14%], P > 0.05, h = 0.08, Figure 7B). Furthermore, a secondary analysis including only 368 
men who had 25(OH)D <50 nmol/L at baseline also revealed no effect of vitamin D 369 
supplementation on secondary hepatitis B vaccine response (P > 0.05).   370 
 371 





We determined the influence of vitamin D on the development of the hepatitis B vaccination in 373 
healthy adults. In study 1, vitamin D status (25(OH)D and 1,25(OH)2D) at the time of initial 374 
vaccination influenced the subsequent secondary hepatitis B vaccine response: low vitamin D 375 
status was associated with poorer hepatitis B vaccine response (Figure 3). Analysis controlling 376 
for demographic, anthropometric, and lifestyle factors, revealed that vitamin D sufficient men, 377 
but not women, were nearly 2 times more likely to be responders to the hepatitis B vaccine than 378 
those with serum 25(OH)D of <50 nmol/L. These differences may be explained by lower serum 379 
25(OH)D and 1,25(OH)2D in men and a lower proportion of men achieving vitamin D 380 
sufficiency compared to women. Indeed, the hepatitis B vaccine response was poorer in men than 381 
women. Furthermore, hepatitis B vaccine response was associated with seasonal alterations in 382 
serum 25(OH)D and 1,25(OH)2D, with poorer hepatitis B vaccine responses in winter than 383 
summer (Figure 4D). The findings of study 1 indicated a possible immunomodulatory role of 384 
vitamin D in the development of hepatitis B vaccine response. Given these findings, and 385 
the high prevalence of serum 25(OH)D <50 nmol/L during winter (81% of persons had serum 386 
25(OH)D <50 nmol/L in study 1), in study 2 we examined the effect of winter vitamin D 387 
supplementation on hepatitis B vaccine response. Study 2, a randomized, placebo-controlled 388 
trial, involved a unique comparison of safe, simulated, casual skin sunlight exposure and oral 389 
vitamin D3 supplementation specifically designed to achieve vitamin D sufficiency. Contrary to 390 
our hypothesis, and despite achieving and maintaining IOM and EFSA defined vitamin D 391 
sufficiency in 95% of participants (Figure 6), vitamin D supplementation beginning 3 days after 392 






The divergent findings of study 1 and 2 are contrary to our hypothesis; however, they are 395 
consistent with animal and human studies that have identified it is the early (within 24 h), rather 396 
than later, stages of orchestrating the development of immunity that are most sensitive to 397 
intervention [40,41]. Indeed, vitamin D, and specifically 1,25(OH)2D, may influence the hepatitis 398 
B vaccine response by stimulating antigen presenting cells, which are pivotal for the initial 399 
capturing, processing and presenting of the antigen at the site of vaccination [42,43]. In animal 400 
models, it has been observed that locally produced 1,25(OH)2D induced migration of dendritic 401 
cells from the site of vaccination to non-draining lymphoid organs, where they can stimulate 402 
antigen specific T and B-cells to mount a strong and persistent antibody response to diphtheria 403 
vaccination [7,8]. Co-administration of 1,25(OH)2D with trivalent influenza vaccine in mice was 404 
shown to enhance both mucosal and systemic specific antibody response [44,45], and highlights 405 
vitamin D as a potential vaccine adjuvant. In addition, previous research in humans has shown 406 
higher IgG antibodies in response to tetanus toxoid vaccination after 9 weeks of vitamin D 407 
supplementation compared to a placebo group [10], which lends further support to the notion of 408 
vitamin D as a potential adjuvant for vaccines more generally.  409 
 410 
In both studies, we were unable to collect an additional blood sample after the third, and final, 411 
hepatitis B vaccine dose; therefore, it remains to be determined whether vitamin D influences the 412 
final development of the hepatitis B vaccine response. As non-responders to initial vaccine dose 413 
tend to be poorer responders to subsequent doses [15], it is reasonable to hypothesise that persons 414 
low in vitamin D at the initial hepatitis B vaccination are more likely to be vaccine non-415 
responders after the full hepatitis B vaccine course (Figure 3). Future studies should however 416 
confirm the influence of vitamin D status at the time of initial vaccination on final antibody status 417 





therefore possible factors other than vitamin D may explain the associations observed between 419 
vitamin D, season and the hepatitis B vaccine response. Previously, body mass index, mood, 420 
sleep and lifestyle (alcohol and smoking use) have been shown to influence the hepatitis B 421 
vaccination response [13-15]. Further, seasonal alterations in infectious disease and compromised 422 
host immunity might influence seasonal alterations in hepatitis B vaccination independent of 423 
vitamin D status [46]. A strength of our studies is that we took account of these factors and 424 
showed they were similar across the seasons (Table 1), and between persons who were vitamin D 425 
sufficient and not (Table 2) and supplementation groups (Table 3). Furthermore, all cause illness, 426 
a marker of host immunity (Tables 1 & 2), and living conditions were also similar. These 427 
similarities strengthen the argument that vitamin D, rather than other factor(s), is responsible for 428 
observed association with hepatitis B vaccination in study 1. Nonetheless, future randomized 429 
control studies using similar supplementation methods as study 2 that improve vitamin D status 430 
before the initial vaccination would verify whether vitamin D status at the time of initial 431 
vaccination is important in the development of the hepatitis B response. 432 
 433 
The objective of these original studies was to explore the influence of vitamin D status on the  434 
hepatitis B vaccination response, with the interventions designed to achieve vitamin D 435 
sufficiency including a 4-week period of low-level SSR (12 exposures) followed by 8-weeks of 436 
maintenance SSR (8 exposures). While vitamin D synthesis is the major established health 437 
benefit of UVR, the latter has immunomodulatory (both suppressive and augmenting) effects, 438 
which may be mediated through vitamin D-dependent and -independent pathways [28,29]. Thus a 439 
previous human study of contrasting design examined for a possible effect of prior acute higher-440 





threshold for 5 days) on the first hepatitis B vaccination response [47]. The investigators did not 442 
relate their findings to vitamin D status. They found no overall impact of UVR on cellular 443 
(lymphocyte stimulation test) or humoral (antibody titre) response to hepatitis B surface antigen, 444 
despite the UVR regime being adequate to reduce other immune responses, i.e. contact 445 
hypersensitivity and natural killer cell activity. Further analysis found individual difference in 446 
susceptibility, with a reduced vaccination response observed in those individuals with a minor 447 
variant of IL-1beta polymorphism; prevalence of the variant is low and further studies are 448 
suggested [48].  449 
 450 
In combination with findings in elderly chronic kidney disease patients [11], our findings in 451 
healthy adults highlight the potential importance of preventing low vitamin D status at the time of 452 
the initial vaccination for the adequate development of the hepatitis B vaccination. Future 453 
research is merited to confirm the influence of vitamin D on the hepatitis B vaccination response 454 
in infants and the elderly, who are at greater risk of poor vitamin D status than healthy young 455 
adults [49], and because the hepatitis B vaccination is mandatory during infancy in several 456 
countries [21,22]. This does not reduce the impact of the current studies findings as many adults 457 
remain unvaccinated because childhood vaccine coverage is ~90% or less and routine infant 458 
hepatitis B vaccination began only recently in some countries (e.g. UK [21-23]). Adult 459 
vaccination is recommended for persons at increased risk of exposure to bodily fluids such as 460 
health care professionals, patients, and those travelling to areas of the world where hepatitis B is 461 
widespread e.g. sub-Saharan Africa, east and southeast Asia and the Pacific Islands [16]. The 462 
1,25(OH)2D findings from study 1 also provide a mechanism by which maintaining vitamin D 463 





B. As more than 50% fail to achieve vitamin D sufficiency during winter months [24-26] future 465 
research to further understand the role of vitamin D on vaccination more broadly is warranted. 466 
The 8% difference in hepatitis B vaccination response between people who were vitamin D 467 
sufficient and 25(OH)D <50 nmol/L, and the 18% difference between winter and summer 468 
(Figures 3A & 4D) are comparable with the effects on the hepatitis B vaccine response shown for 469 
other lifestyle factors e.g. smoking, obesity and poor sleep  [13,15]. Of particular clinical interest, 470 
the winter vaccine response (44% anti-HBs titers ≥10 mIU/mL) was poorer than typically 471 
expected after two hepatitis B vaccine doses (50–90%: Figure 4) [50]. Therefore, rather than 472 
restoring vitamin D sufficiency from its winter nadir, as in study 2, we suggest maintaining year-473 
round vitamin D sufficiency, and where necessary preventing the decline in the end of summer 474 
serum 25(OH)D by commencing vitamin D supplementation in late summer or early autumn and 475 
continuing until spring (~6 months). To maintain end of summer serum 25(OH)D individuals 476 
should aim to achieve current IOM and EFSA vitamin D dietary intake recommendations 477 
[19,20]. We achieved this in study 2 with a daily 400 IU oral vitamin D3 dose (Figure 6). Oral 478 
vitamin D3 supplementation is recommended in the autumn and winter because unlike simulated 479 
sunlight there is no time burden for an individual; no requirement for bulky irradiation cabinets; 480 
and oral vitamin D3 supplementation is effective regardless of sun reactive skin type [51]. 481 
Further, even very low sub-sunburn UVR doses were recently shown to cause skin cell DNA 482 
damage in easy-burning skin types [52]. Low-level sunlight exposure, as used in study 2, may 483 
however provide benefits to human health additional to vitamin D synthesis, and this is an active 484 







In a prospective cohort study of 447 healthy adults (study 1), vitamin D sufficiency was rare 488 
during the UK winter, and fewer people responded to the hepatitis B vaccination than during the 489 
summer. In study 1, poorer vitamin D status (serum 1,25(OH)2D ≤120 pmol/L and 25(OH)D ≤40 490 
nmol/L) at the time of initial vaccination was associated with fewer healthy adults responding to 491 
the hepatitis B vaccine. In a subsequent randomized control trial (study 2), vitamin 492 
D supplementation (oral or via simulated sunlight exposure) that began 3 days after the initial 493 
vaccination, and achieved vitamin D sufficiency within 5 weeks, did not influence the hepatitis B 494 
vaccination response. Randomized control trials that manipulate vitamin D status before the 495 
initial vaccination are warranted to confirm the influence of vitamin D status at the time of initial 496 
vaccination on the hepatitis B vaccine response. In accordance with the findings of the 497 
prospective cohort study (study 1), avoiding low vitamin D status at the time of the initial 498 
hepatitis B vaccination, by maintaining year-round vitamin D sufficiency, might 499 
be recommended to optimise the response to hepatitis B vaccination. This is particularly 500 
important for persons that rely on effective vaccination prophylaxis such as health care 501 
professionals and patients regularly exposed to bodily fluids. 502 
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Table 1. Study 1 baseline participant demographics, anthropometrics, lifestyle behaviors, sleep, mood and all cause illness in cohorts recruited across seasons 
  Winter  Spring Summer Autumn 
 All  
n = 447 
n = 88 
 
n = 63 n = 115 n = 181 
Demographics      
Age (years) 21.7 ± 3.0 21.5 ± 3.0 22.1 ± 3.2 21.9 ± 3.0 21.5 ± 3.1 
Ethnicity, Caucasian [n (%)] 434 (97) 85 (97) 62 (98) 109 (96) 178 (98) 
 
     
Anthropometrics      
Height (m) 1.73 ± 0.08  1.73 ± 0.09 1.71 ± 0.09 1.75 ± 0.08 1.71 ± 0.08 
Body mass (kg) 71.8 ± 10.8 72.1 ± 11.3 70.8 ± 10.8 74.0 ± 10.7  70.5 ± 10.5 
BMI (kg/m2) 24.0 ± 2.7 23.9 ± 2.8 24.2 ± 2.7 24.1 ± 2.6  23.9 ± 2.7 
      
Lifestyle behaviors      
Alcohol user, [n (%)] 376 (88) 76 (93) 50 (82) 99 (87) 151 (88) 
Smoker, [n (%)] 259 (58) 53 (61) 38 (60) 71 (62) 97 (54) 
      
Sleep night before initial vaccination      
Duration (h) 6.4 ± 0.8 6.3 ± 0.7 6.4 ± 0.5 6.3 ± 0.9 6.6 ± 0.9 
Quality (very poor = 1 to very good = 4) 1.7 ± 0.8 1.7 ± 0.8 1.6 ± 0.7 1.8 ± 0.8 1.6 ± 0.8 
      
Contraception (n = 138)1      
None 36 (26) 7 (19) 4 (11) 5 (14) 20 (56) 
COCP 50 (36) 9 (18) 15 (30) 5 (10) 21 (42) 
POP 9 (7) 2 (22) 2 (22) 1 (11) 4 (45) 
Injection 8 (6) 2 (25) 0 (0) 1 (12) 5 (63) 
Implant 35 (25) 9 (26) 6 (17) 5 (14) 15 (43) 
      
Mood before initial vaccination2      
Vigor 8.4 ± 3.0 8.5 ± 3.0 7.3 ± 3.1 8.6 ± 2.8 8.7 ± 3.1 
Anger 0.9 ± 1.6 0.6 ± 1.1 0.7 ± 1.5 1.0 ± 1.6 0.9 ± 1.7  
Tension 4.8 ± 3.4  4.1 ± 3.1  4.7 ± 3.7 4.3 ± 3.1 5.3 ± 3.5 
Confusion 2.3 ± 2.4 2.4 ± 2.8 1.8 ± 1.9 2.5 ± 2.4 2.3 ± 2.5  
Depression 0.7 ± 1.6 0.6 ± 1.1 0.6 ± 2.0 0.7 ± 1.3 0.8 ± 1.7 
Fatigue 4.2 ± 3.0 3.6 ± 2.9 4.3 ± 3.3 4.2 ± 2.8 4.4 ± 3.0 
 











Values presented as mean ± SD, unless otherwise stated. COCP, combined oral contraceptive pill, POP, progesterone-only pill. * P < 0.05 lower than autumn. 
Notes: 1Female contraception data collected from a female specific questionnaire (n = 37 excluded from final data analysis). 2Greater scores indicate a greater 





Table 2. Study 1 baseline participant demographics, anthropometrics, lifestyle behaviors, sleep, 
mood and all cause illness in those with serum 25(OH)D <50 nmol/L and ≥50 nmol/L 
 
 Serum 25(OH)D 
 <50 nmol/L 
n = 194 
≥50 nmol/L 
n = 253 
Demographics   
Men [n (%)] 139 (72) 133 (53) 
Women [n (%)] 55 (28) 120 (47) 
Age (years) 21.3 ± 2.9 22.0 ± 3.2 
Ethnicity, Caucasian [n (%)] 186 (96) 248 (98) 
   
Anthropometrics   
Height (m) 1.74 ± 0.08  1.71 ± 0.09 
Body mass (kg) 73.4 ± 10.8 70.1 ± 10.7 
BMI (kg/m2) 24.2 ± 2.8 23.9 ± 2.6 
   
Lifestyle behaviors   
Alcohol user, [n (%)] 167 (86) 209 (83) 
Smoker, [n (%)] 122 (63) 137 (54) 
   
Sleep night before initial vaccination   
Duration (h) 6.6 ± 0.7 6.3 ± 0.9 
Quality (very poor = 1 to very good = 4) 1.7 ± 0.7 1.7 ± 0.8 
   
Contraception (n = 138)1   
None 14 (33) 22 (23) 
COCP 10 (23) 40 (43) 
POP 2 (5) 7 (7) 
Injection 4 (9) 4 (4) 
Implant 13 (30) 22 (23) 
Mood before initial vaccination2   
Vigor 8.4 ± 3.1 8.4 ± 3.0 
Anger 0.8 ± 1.4 0.9 ± 1.6 
Tension 4.7 ± 3.5  4.8 ± 3.3  
Confusion 2.5 ± 2.6 2.2 ± 2.3 
Depression 0.8 ± 1.8 0.7 ± 1.4 
Fatigue 4.2 ± 3.0 4.3 ± 3.0 
 





Values presented as mean ± SD unless otherwise stated. COCP, combined oral contraceptive pill, POP, 
progesterone-only pill. There were no significant differences between vitamin D sufficient and insufficient 
participants in demographic, anthropometrics, lifestyle behaviors, sleep, mood or all cause illness before the initial 
hepatitis B vaccination at baseline. Notes: 1Female contraception data collected from a female specific 
questionnaire (n = 37 excluded from final data analysis). 2Greater scores indicate a greater feeling of the mood 





Table 3. Study 2 baseline participant demographics, anthropometrics, lifestyle behaviors, sleep and mood in solar simulated radiation (SSR), 
SSR placebo (SSR-P) oral vitamin D3 (ORAL) and oral placebo (ORAL-P) supplemented groups 
 
 SSR  
n = 30 
SSR-P  
n = 28 
ORAL 
n = 32 
ORAL-P  
n = 29 
Demographics      
Age (years) 21.5 ± 3.1 21.7 ± 3.4 20.9 ± 2.7 21.4 ± 3.0 
Ethnicity (Caucasian) [n (%)] 29 (97) 28 (100) 32 (100) 29 (100) 
Skin type (I, II, III, IV) [n (%)]1 3 (10), 8 (27),  
14 (46), 5 (17) 
2 (7), 10 (36),  
13 (46), 3 (11) 
3 (9), 11 (34),  
13 (41), 5 (16) 
2 (7), 9 (31),  
15 (52), 3 (10) 
Anthropometrics      
Height (m) 1.78 ± 0.05 1.77 ± 0.05 1.78 ± 0.07 1.78 ± 0.06 
Body mass (kg) 76.7 ± 11.6 76.8 ± 9.7 75.7 ± 12.3 77.5 ± 10.8 
BMI (kg/m2) 24.3 ± 3.3 24.4 ± 2.8 24.9 ± 2.8 24.9 ± 2.8 
     
Lifestyle behaviors      
Alcohol user [n (%)] 23 (77) 22 (79) 26 (81) 23 (77) 
Smoker [n (%)] 17 (57) 16 (57) 17 (53) 11 (38) 
Sleep night before initial vaccination      
Duration (h) 6.2 ± 0.8 5.9 ± 1.4 5.8 ± 1.5 5.8 ± 1.8 
Quality (very poor = 1 to very good = 4) 2.9 ± 0.7 2.8 ± 0.7 2.8 ± 0.7 2.8 ± 0.7 
Mood before initial vaccination2     
Vigor 8.0 ± 3.4 9.0 ± 2.9 7.1 ± 2.9 8.2 ± 3.2 
Anger 1.0 ± 1.8 1.5 ± 2.5 1.2 ± 2.0 0.7 ± 1.6 
Tension 3.0 ± 2.2 3.6 ± 3.4 3.2 ± 3.3 2.6 ± 2.1 
Confusion 2.6 ± 3.2 2.5 ± 2.9 1.7 ± 2.1 1.5 ± 1.9 
Depression 0.7 ± 1.8 1.4 ± 2.7 0.6 ± 1.6 0.3 ± 0.6 
Fatigue 3.6 ± 2.7 4.9 ± 3.2 4.1 ± 3.5 4.1 ± 3.1 
Values presented as mean ± SD unless otherwise stated. There were no significant differences between supplemented groups in demographics, 
anthropometrics, lifestyle behaviors, sleep or mood before the initial hepatitis B vaccination at baseline (P > 0.05). Notes: 1Skin types are based on Fitzpatrick 








FIGURE 1.   Schematic of Study 1 and 2 procedures. Study 1 investigated the influence of 
vitamin D status at the time of the initial hepatitis B vaccination on the secondary 
antibody response to hepatitis B vaccination. Study 2 investigated the effect of 
vitamin D supplementation by solar simulated radiation (SSR), oral vitamin D3 
(ORAL), or placebo (SSR-P or ORAL-P) after the initial hepatitis B vaccination on 
secondary hepatitis B vaccine response. Needle and bottle icon represents hepatitis 
B vaccination doses. Blood tube icon represents when blood samples were obtained 
for serum 25(OH)D, 1,25(OH)2D and hepatitis B antibody titer measurements. 
FIGURE 2.   Flow diagram indicating the numbers of participants assessed for eligibility, 
recruited, available at follow-up, and analyzed as part of Study 1. Anti-HBs; 
antibodies against hepatitis B antigen.  
FIGURE 3.   Secondary hepatitis B vaccine response in those with serum 25(OH)D <50 nmol/L  
(n = 194) and serum 25(OH)D ≥50 nmol/L (n = 253 adults, panel A), and low, 
medium and high serum 25(OH)D (panel B, n = 447) and low, medium and high 
1,25(OH)2D terciles (panel C, n = 444). † P < 0.1, lower percentage of secondary 
hepatitis B vaccination responders (anti-HBs ≥10 mIU/mL) in participants with 
25(OH)D <50 nmol/L than vitamin D sufficient participants. ‡ P < 0.05, lower 
percentage of secondary hepatitis B vaccination responders (anti-HBs ≥10 mIU/mL) 
in low 25(OH)D and 1,25(OH)2D terciles compared to medium 25(OH)D and high 





FIGURE 4.   Seasonal variation in serum 25(OH)D (panel A), percentage of participants 
categorized as vitamin D sufficient (25(OH)D ≥50 nmol/L; panel B), serum 1, 
25(OH)2D (panel C), and percentage of secondary hepatitis B vaccination 
responders (anti-HBs ≥10 mIU/mL; panel D) in 447 healthy, young men (n = 272) 
and women (n = 175) residing in the UK. Panels A and C data are mean ± SD. Panels 
B and D are percentages represented by vertical bars. a, lower than summer (P < 
0.05). b, lower than autumn (P < 0.05). c, lower than spring (P < 0.05).  
FIGURE 5.   CONSORT flow diagram indicating the numbers of participants assessed, recruited, 
randomly assigned, and analyzed as part of Study 2. Anti-HBs; antibodies against 
hepatitis B antigen. Vitamin D = SSR; solar simulated radiation, ORAL; oral 
vitamin D3. Placebo = SSR-P; solar simulated radiation placebo, ORAL-P; oral 
placebo. 
FIGURE 6.   Serum 25(OH)D (panels A & D), percentage of participants categorized as vitamin 
D sufficient (serum 25(OH)D ≥50 nmol/L, panels B & E), serum 1,25(OH)2D 
(panels C & F) in response to 12-weeks of vitamin D supplementation by solar 
simulated radiation (SSR) and oral vitamin D3 (ORAL). Panels A, B & C show 
comparisons of individual vitamin D and placebo supplementation groups (SSR, 
SSR-P, ORAL & ORAL-P). Panels D, E & F show combined vitamin D 
supplementation (SSR & ORAL) vs combined placebo (SSR-P & ORAL-P) groups. 
† P < 0.05, greater than baseline. ‡ P < 0.05, greater than week 5. * P < 0.05, greater 
than SSR-P. § P < 0.05, greater than ORAL-P & SSR-P. # P < 0.05, greater than 
combined SSR-P & ORAL-P. Data are mean ± SD (panels A, C, D & F) and vertical 





Figure 7  Percentage of participants categorized as secondary hepatitis B vaccine responders 
(anti-HBs ≥10 mIU/mL, panels A & B) after 12-weeks of vitamin D 
supplementation by solar simulated radiation (SSR) and oral vitamin D3 (ORAL). 
Panel A compares individual vitamin D and placebo supplementation groups (SSR, 
SSR-P, ORAL & ORAL-P). Panel B shows combined vitamin D supplementation 
(SSR & ORAL) vs combined placebo (SSR-P & ORAL-P) groups. There was no 
difference in vaccine response between individual vitamin D and placebo 
supplementation groups (panel A, SSR 60%, SSR-P 57%, ORAL 56%, ORAL-P 
52%, P > 0.05) or between combined vitamin D and placebo groups (panel B, SSR 
and ORAL 58% vs SSR-P and ORAL-P 54%, P > 0.05). 
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Assessed for eligibility, n = 1268
Participants recruited, n = 1103
Follow-up blood sample, n = 679





<18 years of age, n = 108
Declined to participate, n = 57
Discontinued study, n = 424
(Withdrew from study, n = 302; 
Withdrew from army training, n = 22; 
Blood sample not given, n = 100)
Excluded from analysis, n = 232
(Atypical vaccination schedule, n = 193; 
Detectable baseline hepatitis B antibody
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SSR, n = 58
Discontinued 
intervention
Due to time commitment, 
n = 18
Excluded, n = 10
(<80% intervention 
compliance, n = 4; 
Atypical vaccination 
schedule, n = 2; 
Detectable baseline anti-
HBs, n = 4)
Assessed for eligibility, n = 434
Randomly assigned, n = 231
Declined to participate or 
excluded, n = 203
(Declined to participate, n = 73; Did 
not meet inclusion criteria, n = 19; 
Withdrew consent due to time 
commitment, n = 111)
Analyzed for secondary 
anti-HBs, n = 30
SSR-P, n = 52
Discontinued 
intervention
Due to time commitment, 
n = 16
Excluded, n = 8
(<80% intervention 
compliance, n = 4;
Atypical vaccination 
schedule, n = 2;
Detectable baseline anti-
HBs, n = 1; Indeterminate 
anti-HBs, n =1)
ORAL, n = 59
Discontinued 
intervention
Due to time commitment, 
n = 17
Excluded, n = 10
(<80% intervention 
compliance, n = 4; 
Atypical vaccination 
schedule, n = 4; 
Detectable baseline anti-
HBs, n = 1; Indeterminate 
anti-HBs, n =1)
ORAL-P, n = 62
Discontinued 
intervention
Due to time commitment, 
n = 22
Excluded, n = 11
(<80% intervention 
compliance, n = 7; 
Atypical vaccination 
schedule, n = 2; 
Detectable baseline anti-
HBs, n = 2)
Analyzed for secondary 
anti-HBs, n = 28
Analyzed for secondary 
anti-HBs, n = 32
Analyzed for secondary 
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